Biomarker Panel Predicts CRT Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting response to cardiac resynchronization therapy (CRT) in heart failure patients are inadequate, as there is no validated approach to identify which patients will benefit from CRT, and differentiating non-responders can be challenging, leading to variable outcomes and increased risk of major adverse cardiovascular events.
Innovation Solution
A biomarker panel including CRP, SGP-130, sIL-2R, sTNFR-II, IFN-γ, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-4 is used to predict CRT response, identify non-responders, and monitor disease progression by quantifying biomarker levels in patient samples, allowing for personalized therapy adjustments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current prediction methods are used for CRT therapy, then the simplicity of assessment is maintained, but the accuracy of predicting CRT response deteriorates
Solution Approach 1:
The patent combines multiple individual biomarker assessments into a unified biomarker panel that collectively predicts CRT response. By merging data from several biomarkers (including BNP, NT-proBNP, and other cardiac markers) into a single integrated assessment tool, the system achieves higher predictive accuracy while presenting a consolidated result to clinicians.
Solution Approach 2:
The biomarker panel serves multiple functions simultaneously: it predicts CRT response, identifies non-responders, guides therapy selection, and monitors treatment outcomes. This multi-functional approach consolidates what would otherwise require multiple separate assessment tools into a single universal screening system.
2Reliability
If a single biomarker is used for prediction, then the simplicity of testing is maintained, but the reliability of prediction deteriorates
Solution Approach 1:
The patent merges information from multiple biomarkers into a unified prediction model. Rather than relying on any single biomarker in isolation, the system integrates data from several cardiac biomarkers to produce a more reliable and robust prediction of CRT response, thereby overcoming the limitations of individual markers.
3Measurement precision
If comprehensive biomarker panels are implemented, then the accuracy of patient stratification is improved, but the cost and complexity of testing increases
Solution Approach 1:
The patent segments the comprehensive biomarker assessment into distinct functional components: a core set of essential biomarkers for basic prediction, and additional biomarkers that can be selectively added based on patient-specific needs. This segmentation allows the system to maintain high accuracy while enabling flexible scaling of testing complexity.
Solution Approach 2:
The system implements a tiered approach where a minimal sufficient set of biomarkers provides adequate prediction for most patients, while allowing for expanded panels when clinical circumstances warrant more comprehensive assessment. This partial action principle avoids unnecessary complexity for routine cases while maintaining the option for full comprehensive testing when needed.
Data Source
AI summary
Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data with respect to medical devices and methods, amongst other things. In an embodiment, the disclosure can include a method of predicting the likelihood of response to CRT therapy. The method can include quantifying levels of one or more biomarkers in a biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein.